Bas Jm Peters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bas Jm Peters has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anke-Hilse Maitland-Van der Zee
Department of Pulmonary Medicine, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
1 shared publication - Anthonius de Boer
Dutch Medicines Evaluation Board Utrecht The Netherlands
1 shared publication - Frank L. J. Visseren
University Medical Center Utrecht
1 shared publication - Olaf H. Klungel
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Springer Nature in Genome Medicine
- Vol. 1 (12) , 120
Pharmacogenomic insights into treatment and management of statin-induced myopathy
Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.
- 1 January 2009
- Published by Springer Nature in Genome Medicine
- Vol. 1 (12) , 120
Open AccessPharmacogenomic insights into treatment and management of statin-induced myopathy
Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.